« Previous
Next »
Titles
- E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)1
- Early learning and child care: agencies have helped address fragmentation and overlap through improved coordination : report to the Chairwoman, Committee on Education and the Workforce, House of Representatives1
- Early learning and child care: overview of federal investment and agency coordination : testimony before the Subcommittee on Early Childhood, Elementary, and Secondary Education, Committee on Education and the Workforce, House of Representatives1
- Effect of a price transparency intervention in the electronic health record on clinician ordering of inpatient laboratory tests1
- Effects of Medicare Advantage enrollment on beneficiary risk scores1
- Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders1
- Emerging infectious diseases: actions needed to ensure improved response to Zika virus disease outbreaks : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Engaging families in improving the health care system for children with special health care needs1
- Enhancements needed in the tracking and collection of Medicare overpayments identified by ZPICS and PSCS1
- Errors originating in hospital and health-system outpatient pharmacies1
- Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff1
- Evaluating drug effects on the ability to operate a motor vehicle1
- Evaluating the impact of the laborist model of obstetric care on maternal and neonatal outcomes1
- Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff1
- Evaluation of the Minnesota accountable health model: executive summary1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
- Expanding access to low-cost, high-quality tertiary care: spreading the Narayana Health model beyond India1
- Experience has taught us that high-risk pools do not serve consumers well1
- Explaining health care reform: questions about health insurance subsidies1